🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Caigang Liu clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Caigang Liu as lead sponsor. Synced 26 Sep 2026
4Current trials
1Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Caigang Liu is the lead sponsor of 4 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are ARX788, Cadonilimab and Carboplatin. The most-studied condition is Colorectal Cancer.

ClinicalTrials.gov trials by status

  • Recruiting125%
  • Not yet open125%
  • Active, closed125%
  • By invitation125%

Trials by phase

  • Not applicable250%
  • Phase 3125%
  • Phase 2/3125%
01

Clinical trials sponsored by Caigang Liu

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
NCT06566755 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 3 Recruiting 2024-02 China
Efficacy and Safety of Sanyong Jiedu Granules in Treating Lumps-Type Non-Lactational Mastiti
NCT07512648 · ClinicalTrials.gov ↗ · Plasmacytic Mastitis, Granulomatous Lobular Mastitis
Not applicable Not yet open 2026-03 China
Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
NCT06881550 · ClinicalTrials.gov ↗ · Breast Cancer
Not applicable By invitation 2024-12 China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05426486 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer
Phase 2/3 Active, closed 2022-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Caigang Liu trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Caigang Liu trials

5 conditions
Colorectal Cancer1HER2-positive Breast Cancer1Breast Cancer1Plasmacytic Mastitis1Granulomatous Lobular Mastitis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China41

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Colorectal Cancer

SponsorTrials
Fudan University19
Zhejiang University6
A2 Biotherapeutics3
Nanchong Central Hospital3
First Affiliated Hospital of Chongqing Medical University3
Singlera Genomics3
Verastem2
Exelixis2
IDEAYA Biosciences2
Exact Sciences Corporation2

Sponsors with the most current trials registered for this condition.

06

Questions about Caigang Liu trials

How many clinical trials does Caigang Liu sponsor?

Caigang Liu is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Caigang Liu trials recruiting?

Yes. 1 of its 4 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Caigang Liu testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are ARX788 (1), Cadonilimab (1), Carboplatin (1), Docetaxel (1) and Pertuzumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.